Table 3.
Sign/Symptom | Aducanumab (2) | Lecanemab (4) | Donanemab (5) | Gantenerumab (6) |
---|---|---|---|---|
Headache (%) | 13 | 12.5 | 7.6 | 9.6–12.5 |
Dizziness (%) | 4 | 8.3 | 8.4 | 7.7–10.4 |
Confusion/altered mental status (%) | 5 | ? | ? | ? |
Visual disturbance/eye disorders (%) | 2 | ? | ? | 5.9–8.8 |
Nausea (%) | 2 | 8.3 | 10.7 | ? |
New onset seizure(s) (%) | ? | ? | ? | ? |
Signs/symptoms of ARIA by antibody ranked by incidence. Incidence is presented as a percentage of symptomatic patients within the total number of patients with the observation of ARIA. [?] indicates data not available.